Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8896 to 8905 of 8905 results

  1. World's first gene editing therapy for blood disorder to be available to hundreds of patients in England

    Patients in England with severe beta-thalassaemia will be amongst the first in Europe to benefit from one-time gene therapy exagamglogene autotemcel.

  2. 14,000 women at risk of fractures after the menopause to benefit from bone disease drug

    Over 14,000 people to benefit after NICE published final guidance recommending abaloparatide as an option for treating osteoporosis after menopause, if there is a very high risk of fracture.

  3. NICE disappointed companies unwilling to offer fair price to make Enhertu available for advanced breast cancer

    Daiichi Sankyo and partner company AstraZeneca have been unwilling to offer a price that would enable NICE to recommend Enhertu as cost effective for the NHS in final guidance published today.

  4. New injectable immunotherapy treatment for rare form of triple negative breast cancer recommended by NICE

    People with triple negative breast cancer that has spread to other parts of the body may soon benefit from pembrolizumab in combination with chemotherapy.

  5. How my experience as a patient helped shape NICE guidelines for colorectal cancer

    Following my surgery and treatment for colorectal cancer in 2014, I wanted to contribute to research in the cancer field and hopefully improve things for patients in the future.

  6. A 'safe space' for addressing complex health technology assessment challenges

    Nick Crabb discusses how we’re developing a collaborative space for research and development, to help us create new methods and processes for health technology assessment.

  7. NICE recommends several treatment options to help with rheumatoid arthritis

    Around 25,000 people with moderate rheumatoid arthritis that has not responded to conventional therapies are set to benefit from the recommendations announced today.

  8. Change in treatment for people with early breast cancer to benefit around 4,000

    Around 4,000 people are set to benefit from a change in treatment for early breast cancer following provisional approval by NICE of abemaciclib in combination with hormone therapy.

  9. NICE recommends treatment options for severe pregnancy sickness

    Nausea and vomiting, often referred to as morning sickness, is common in pregnancy. Close to 80% of pregnant women experience these symptom.

  10. NICE joins the shared commitment to public involvement in research

    Working alongside people and communities is an essential tool in helping to improve?the impact of our guidance and continuing to get the best care to people and communities, fast, while ensuring value for the taxpayer.